Incidence of donor‐specific antibodies in kidney transplant patients following conversion to an everolimus‐based calcineurin inhibitor‐free regimen
- 28 April 2013
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 27 (3), 455-462
- https://doi.org/10.1111/ctr.12127
Abstract
Scarce data exist regarding the incidence of donor‐specific antibodies (DSAs) in kidney transplant patients receiving everolimus‐based immunosuppression without calcineurin inhibitors (CNIs). The aim of this retrospective case–control study was to compare the incidence of de novo DSAs in patients converted to an everolimus‐based regimen without CNIs with that seen in patients maintained on CNIs. Sixty‐one DSA‐free kidney transplant patients who had been converted to an everolimus‐based regimen (everolimus group) were compared to 61 other patients maintained on CNIs‐based regimen (control group). Patients were matched according to age, gender, induction therapy, date of transplantation, and being DSA‐free at baseline. At last follow‐up, the incidence of DSAs was 9.8% in the everolimus group and 5% in the control group (p = ns). In the everolimus group, the increased incidence of DSAs between baseline and last follow‐up was statistically significant. Antibody‐mediated rejection occurred in 6.5% in the everolimus group and 0% in the CNIs group. The incidence of DSAs is numerically increased in kidney transplant patients treated with an everolimus‐based without CNIs. A study including a larger number of patients is required to determine whether a CNI‐free everolimus‐based immunosuppression significantly increases DSAs formation.Keywords
This publication has 17 references indexed in Scilit:
- Does Everolimus Increase Donor-Specific HLA Antibodies in Kidney Transplant Recipients?American Journal of Transplantation, 2012
- Immunosuppressive Potential and Side Effects of EverolimusAmerican Journal of Transplantation, 2012
- Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month StudyTransplantation, 2011
- Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept StudyAmerican Journal of Transplantation, 2011
- Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney TransplantationJournal of the American Society of Nephrology, 2010
- Everolimus Plus Reduced‐Exposure CsA versus Mycophenolic Acid Plus Standard‐Exposure CsA in Renal‐Transplant RecipientsAmerican Journal of Transplantation, 2010
- Transplant Outcomes and Economic Costs Associated with Patient Noncompliance to ImmunosuppressionAmerican Journal of Transplantation, 2009
- Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT TrialTransplantation, 2009
- Transplant GlomerulopathyAmerican Journal of Transplantation, 2008
- Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal TransplantationJournal of the American Society of Nephrology, 2006